Evidence-based policy choices for efficient and equitable cervical cancer screening programs in low-resource settings

Cancer Medicine

Volumn 6, Issue 8, 2017, Pages 2008-2014

  Campos, Nicole G ^a   Tsu, Vivien ^b   Jeronimo, Jose ^b   Mvundura, Mercy ^b   Kim, Jane J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b PATH   (United States)

Author keywords

Cancer screening; Cervical cancer; Cost effectiveness analysis; Health policy; HPV DNA test

Indexed keywords

CANCER SCREENING; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED MEDICINE; HEALTH CARE DISPARITY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; MATHEMATICAL MODEL; NOTE; PRIORITY JOURNAL; PROCESS MODEL; RESOURCE MANAGEMENT; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; COMPLICATION; COMPUTER SIMULATION; DECISION MAKING; DEVELOPING COUNTRY; DISEASE MANAGEMENT; EARLY CANCER DIAGNOSIS; FEMALE; MASS SCREENING; PAPILLOMAVIRUS INFECTION; THEORETICAL MODEL; UTERINE CERVIX TUMOR; VIROLOGY;

CHOICE BEHAVIOR; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DISEASE MANAGEMENT; EARLY DETECTION OF CANCER; FEMALE; HEALTH POLICY; HEALTH RESOURCES; HUMANS; MASS SCREENING; MODELS, THEORETICAL; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 85023602260     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.1123     Document Type: Note

References (46)

1. Walboomers, J. M., M. V. Jacobs, M. M. Manos, F. X. Bosch, J. A. Kummer, et al. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19.
2. Rodriguez, A. C., M. Schiffman, R. Herrero, A. Hildesheim, C. Bratti, et al. 2010. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J. Natl Cancer Inst. 102:315–324.
3. Schiffman, M., and N. Wentzensen. 2013. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol. Biomarkers Prev. 22:553–560.
4. Li, N., S. Franceschi, R. Howell-Jones, P. J. Snijders, and G. M. Clifford. 2011. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int. J. Cancer 128:927–935.
5. Sankaranarayanan, R., B. M. Nene, S. S. Shastri, K. Jayant, R. Muwonge, et al. 2009. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 360:1385–1394.
6. Denny, L., L. Kuhn, C. C. Hu, W. Y. Tsai, and T. C. Wright Jr. 2010. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J. Natl Cancer Inst. 102:1557–1567.
7. Ferlay, J., I. Soerjomataram, M. Ervik, R. Dikshit, and S. Eser, et al. (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer.
8. Bruni, L., M. Diaz, L. Barrionuevo-Rosas, R. Herrero, F. Bray, et al. 2016. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob. Health 4:e453–e463.
9. Gavi, the Vaccine Alliance. Countries approved for support. Available at: http://www.gavi.org/results/countries-approved-for-support/(accessed: 8 June 2017).
10. Cervical Cancer Action. Global Progress in HPV Vaccination. Available at: http://www.cervicalcanceraction. org/comments/comments3.php (accessed: 8 June 2017).
11. United Nations Department of Economic and Social Affairs, Population Division. 2013. World Population Prospects, The 2012 Revision. Geneva.
12. Sauvaget, C., J. M. Fayette, R. Muwonge, R. Wesley, and R. Sankaranarayanan. 2011. Accuracy of visual inspection with acetic acid for cervical cancer screening. Int. J. Gynaecol. Obstet. 113:14–24.
13. Kitchener, H. C., P. E. Castle, and J. T. Cox. 2006. Chapter 7: Achievements and limitations of cervical cytology screening. Vaccine 24 (Suppl 3): S3/63–S3/70.
14. Cervical Cancer Action. 2015. Global Progress in HPV DNA Testing for Cervical Cancer Screening. Available at: http://www.cervicalcanceraction.org/comments/comments2.php (accessed: 8 June 2017).
15. Gakidou, E., S. Nordhagen, and Z. Obermeyer. 2008. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med. 5:e132.
16. Campos, N. G., V. Tsu, J. Jeronimo, M. Mvundura, K. Lee, and J. J. Kim. 2015. When and how often to screen for cervical cancer in three low-and middle-income countries: A cost-effectiveness analysis. Papillomavirus Res. 1:38–58.
17. Campos, N. G., V. Tsu, J. Jeronimo, M. Mvundura, K. Lee, et al. 2016. To expand coverage, or increase frequency: quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low-resource settings. Int. J. Cancer 140:1293–1305.
18. Campos, N. G., V. Tsu, J. Jeronimo, D. Njama-Meya, M. Mvundura, and J. J. Kim 2017. Cost-effectiveness of an HPV self-collection campaign in Uganda: Comparing models for delivery of cervical cancer screening in a low-income setting. Health Policy Plan. doi: 10.1093/heapol/czw182.
19. World Health Organization. 2013. WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention, Geneva.
20. Sankaranarayanan, R., P. O. Esmy, R. Rajkumar, R. Muwonge, R. Swaminathan, et al. 2007. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 370:398–406.
21. Shastri, S. S., I. Mittra, G. A. Mishra, S. Gupta, and R. Dikshit, et al. 2014. Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India. J. Natl Cancer Inst. 106: dju009.
22. Qiao, Y. L., J. W. Sellors, P. S. Eder, Y. P. Bao, J. M. Lim, et al. 2008. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 9:929–936.
23. Jeronimo, J., P. Bansil, J. Lim, R. Peck, P. Paul, et al. 2014. A multicountry evaluation of careHPV testing, visual inspection with acetic acid, and papanicolaou testing for the detection of cervical cancer. Int. J. Gynecol. Cancer 24:576–585.
24. Schiffman, M., P. E. Castle, J. Jeronimo, A. C. Rodriguez, and S. Wacholder. 2007. Human papillomavirus and cervical cancer. Lancet 370:890–907.
25. Goldie, S. J., J. D. Goldhaber-Fiebert, and G. P. Garnett. 2006. Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. Vaccine 24(Suppl 3): S3/155–S3/163.
26. World Health Organization. 2001. Macroeconomics and Health: Investing in Health for Economic Development: Report of the Commission on Macroeconomics and Health. World Health Organization, Geneva.
27. WHO. 2014. Comprehensive cervical cancer control: a guide to essential practice, 2nd ed. World Health Organization, Geneva.
28. Institut Catala d’Oncologia. 2014. HPV Information Centre.
29. World Health Organization. Prevention of cervical cancer through screening using visual inspection with acetic acid (VIA) and treatment with cryotherapy: A demonstration project in six African countries: Malawi, Madagascar, Nigeria, Uganda, the United Republic of Tanzania, and Zambia. Geneva.
30. Arrossi, S., L. Thouyaret, R. Herrero, A. Campanera, A. Magdaleno, et al. 2015. Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (the EMA study): a population-based cluster-randomised trial. Lancet Glob. Health. 3:e85–e94.
31. Lazcano-Ponce, E., A. T. Lorincz, A. Cruz-Valdez, J. Salmeron, P. Uribe, et al. 2011. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 378:1868–1873.
32. Sowjanya, A. P., P. Paul, H. Vedantham, G. Ramakrishna, D. Vidyadhari, et al. 2009. Suitability of self-collected vaginal samples for cervical cancer screening in peri-urban villages in Andhra Pradesh India. Cancer Epidemiol. Biomarkers Prev. 18:1373–1378.
33. Moses, E., H. N. Pedersen, S. M. Mitchell, M. Sekikubo, D. Mwesigwa, et al. 2015. Uptake of community-based, self-collected HPV testing vs. visual inspection with acetic acid for cervical cancer screening in Kampala, Uganda: preliminary results of a randomised controlled trial. Trop. Med. Int. Health 20:1355–1367.
34. Santesso, N., R. A. Mustafa, H. J. Schunemann, M. Arbyn, P. D. Blumenthal, et al. 2016. World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer. Int. J. Gynaecol. Obstet. 132:252–258.
35. Blumenthal, P. D., L. Gaffikin, S. Deganus, R. Lewis, M. Emerson, et al. 2007. Cervical cancer prevention: safety, acceptability, and feasibility of a single-visit approach in Accra Ghana. Am. J. Obstet. Gynecol. 196:(407) e401–e408; discussion 407 e408-409.
36. Shiferaw, N., G. Salvador-Davila, K. Kassahun, M. I. Brooks, T. Weldegebreal, et al. 2016. The single-visit approach as a cervical cancer prevention strategy among women with HIV in Ethiopia: successes and lessons learned. Glob. Health Sci. Pract. 4:87–98.
37. Sankaranarayanan, R., R. Anorlu, G. Sangwa-Lugoma, and L. A. Denny. 2013. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa. Vaccine 31(Suppl 5):F47–F52.
38. Bigoni, J., M. Gundar, P. M. Tebeu, A. Bongoe, S. Schafer, et al. 2015. Cervical cancer screening in sub-Saharan Africa: a randomized trial of VIA versus cytology for triage of HPV-positive women. Int. J. Cancer 137:127–134.
39. Catarino, R., P. Vassilakos, S. Scaringella, M. Undurraga-Malinverno, U. Meyer-Hamme, et al. 2015. Smartphone use for cervical cancer screening in low-resource countries: a pilot study conducted in madagascar. PLoS ONE 10:e0134309.
40. Qiao, Y. L., J. Jeronimo, F. H. Zhao, J. Schweizer, W. Chen, et al. 2014. Lower cost strategies for triage of human papillomavirus DNA-positive women. Int. J. Cancer 134:2891–2901.
41. Tebeu, P. M., J. Fokom-Domgue, V. Crofts, E. Flahaut, R. Catarino, et al. 2015. Effectiveness of a two-stage strategy with HPV testing followed by visual inspection with acetic acid for cervical cancer screening in a low-income setting. Int. J. Cancer 136:E743–E750.
42. Joshi, S., R. Sankaranarayanan, R. Muwonge, V. Kulkarni, T. Somanathan, et al. 2013. Screening of cervical neoplasia in HIV-infected women in India. AIDS 27:607–615.
43. Campbell, C., S. Kafwafwa, H. Brown, G. Walker, B. Madetsa, et al. 2016. Use of thermo-coagulation as an alternative treatment modality in a ‘screen and treat’ programme of cervical screening in rural Malawi. Int. J. Cancer 139:908–915.
44. Naud, P. S., R. Muwonge, E. P. Passos, V. Magno, J. Matos, et al. 2016. Efficacy, safety, and acceptability of thermocoagulation for treatment of cervical intraepithelial neoplasia in a hospital setting in Brazil. Int. J. Gynaecol. Obstet. 133:351–354.
45. Kim, J. J., N. G. Campos, S. Sy, E. A. Burger, J. Cuzick, et al. 2015. Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis. Ann. Intern. Med. 163:589–597.
46. Farmer, P., J. Frenk, F. M. Knaul, L. N. Shulman, G. Alleyne, et al. 2010. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet 376:1186–1193.